Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 251 - 275 of 1990 in total

Iptacopan

Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase. This is...
Approved
Investigational
Matched Description: … the glycosyl phosphatidylinositol–anchored proteins that normally anchor 2 membrane proteins, CD55 and ... Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and ... , where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Levomilnacipran

Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is ... [A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does ... [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …

Rubidium Rb-82

Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.
Approved
Investigational

Phenyl salicylate

Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in DB00945 ). Phenyl salicylate may...
Approved
Matched Description: … This compound belongs to the class of organic compounds known as depsides and depsidones. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Miscellaneous Analgesics and Antipyretics …

Ethylhexyl methoxycrylene

Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states . It returns UV filters to their ground states without absorbing sunlight . It is used as a solvent for crystalline UV filters and is easily emulsified and suitable...
Approved
Experimental
Matched Description: … It is used as a solvent for crystalline UV filters and is easily emulsified and suitable for use in various ... lotions, creams, sprays, sticks, and gel formulations [F104]. ... It currently enjoys regional approvals in Canada, the EU, and the US [L2847]. …

Viltolarsen

Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … [A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... cardiac function and is invariably fatal. ... dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Clozapine

Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical". . This low affinity to dopamine receptors results in fewer extrapyramidal side effects,...
Approved
Matched Description: … side effects, notably gastrointestinal hypomotility and orthostatic hypotension. ... [A185747] However, its promiscuity toward the muscarinic and adrenergic receptors can result in other ... Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine …
Matched Categories: … Diazepines, Oxazepines, Thiazepines and Oxepines …

Isoniazid

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Approved
Investigational
Matched Categories: … ethambutol and isoniazid ... rifampicin and isoniazid ... streptomycin and isoniazid ... thioacetazone and isoniazid ... rifampicin, ethambutol and isoniazid …

Omaveloxolone

Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties.[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity...
Approved
Investigational
Matched Description: … adolescents aged 16 years and older. ... Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory ... L45424] The use of omaveloxolone for the treatment of conditions involving mitochondrial dysfunction and …

Crizotinib

Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers...
Approved
Investigational
Matched Description: … used to detect ALK and ROS1 rearrangements. ... and genetic resistance mechanisms crizotinib is prone to. ... Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Benzatropine

Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of...
Approved
Matched Description: … It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the ... [A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500] ... an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and …

Cyclobenzaprine

Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from Amitriptyline by only a single double bond.[A185039,A184982] Since its approval, it has...
Approved
Matched Description: … available for human use since 1977. ... Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been …

Tigecycline

Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Approved
Matched Description: … Food and Drug Administration (FDA) on June 17, 2005. ... Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil …

Clofarabine

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic...
Approved
Investigational
Matched Description: … It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. ... Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …

Infigratinib

Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a...
Approved
Investigational
Matched Description: … [A235174] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Eculizumab

Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Description: … [L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Trichloroethylene

Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic. Environmental exposure,...
Approved
Matched Description: … , is a major concern for human health and has been the subject of numerous incidents and lawsuits. ... It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic ... and as an inhaled obstetrical analgesic. …

Ubrogepant

Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and ... [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and …

Rotigotine

Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours....
Approved
Matched Description: … restless legs syndrome (RLS) in Europe and the United States. ... It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. ... (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and …

Technetium Tc-99m disofenin

Technetium Tc-99m disofenin is a radiopharmaceutical agent used in hepatobiliary imaging for diagnostic purposes. It is well suited for both planar and single photon tomographic scintigraphy to quantitatively measure the function of liver, gallbladder and bile ducts and detect any anatomical changes in the hepatobliary system. It is available as...
Approved
Matched Description: … the function of liver, gallbladder and bile ducts and detect any anatomical changes in the hepatobliary ... It is well suited for both planar and single photon tomographic scintigraphy to quantitatively measure ... Technetium Tc-99m is a metastable nuclear isomer and disofenin is an iminodiacetic acid derivative with …
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins ... Hepatic and Reticulo Endothelial System …

Sodium tartrate

Sodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing. Sodium tartrate is generally recognized as safe (GRAS) as a direct human food ingredient. It acts as an emulsifier and pH...
Approved
Matched Description: … Sodium tartrate is generally recognized as safe (GRAS) as a direct human food ingredient. ... It acts as an emulsifier and pH control agent in food products [L2590]. ... tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and …
Matched Categories: … Alimentary Tract and Metabolism …

Faricimab

Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … [L42305] In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended faricimab ... vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and ... retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Avelumab

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) ... ] and Health Canada,[L48171] respectively. ... to block its interaction with its receptors found on T cells and antigen-presenting cells. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Fluvoxamine

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised...
Approved
Investigational
Matched Description: … It was launched in the US in December 1994 and in Japan in June 1999. ... Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …
Displaying drugs 251 - 275 of 1990 in total